SCHEMBL2090476

SCHEMBL2090476

COCc1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
ALOX12 P18054 1/20 0.57
MAPT P10636 6/20 0.57
MEN1 O00255 2/20 0.56
USP2 O75604 1/20 0.56
POLB P06746 3/20 0.54
GAA P10253 1/20 0.54
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
LMNA P02545 1/20 0.51
RECQL P46063 1/20 0.51
BLM P54132 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
RAB9A P51151 2/20 0.50
NOTUM Q6P988 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090020 0.85 NPC1 (0.57) KMT2AALOX12MAPTPOLBKDM4E
SCHEMBL6003569 0.84 KMT2A (0.55) KMT2AALOX12MAPTMEN1USP2
SCHEMBL2088807 0.83 MAPT (0.69) KMT2AMAPTMEN1USP2POLB
SCHEMBL5115763 0.83 MAPT (0.58) KMT2AMAPTMEN1USP2POLB
SCHEMBL932162 0.81 NPC1 (0.55) KMT2AALOX12MAPTMEN1USP2
SCHEMBL14438048 0.81 KMT2A (0.62) KMT2AALOX12MAPTMEN1POLB
SCHEMBL8890866 0.80 NOTUM (0.74) KMT2AMAPTMEN1USP2POLB
SCHEMBL2093817 0.80 RAB9A (0.53) MAPTUSP2POLBKDM4EALDH1A1
SCHEMBL12419595 0.80 MAPT (0.46) KMT2AMAPTMEN1USP2POLB
SCHEMBL2640766 0.79 ALDH1A1 (0.70) KMT2AALOX12MAPTMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KMT2A 3324/4885ALOX12 1886/4885MAPT 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.